Arkema Empowers SEQENS: Exclusive License Granted for PEKK Manufacturing Technology

SEQENS, a global leader in pharmaceutical and specialty market solutions, is advancing its collaboration with Arkema by securing an exclusive technology license for the production of PEKK intended for long-term implantable applications. This milestone builds upon a longstanding 15-year partnership, leveraging Arkema's specialized PEKK technology and SEQENS' expertise in polymer manufacturing for the pharmaceutical and life sciences sectors.

PEKK, a high-performance polymer under Arkema's Kepstan® brand, is widely used in rigorous industries such as aerospace. SEQENS' IMPEKK materials, tailored specifically for long-term medical implants, offer a potential alternative to traditional titanium and PEEK materials. These advanced materials will be distributed globally by SEQENS through an established network of partners, including leading manufacturers, 3D printing firms, and distributors, reinforcing SEQENS' commitment to delivering innovative solutions to the healthcare industry.

Chiara Bergerone, Managing Director of Seqens' Innovative Business Unit, expresses pride in collaborating with Arkema and leveraging their specialized expertise in PEKK polymer technology. Seqens brings extensive experience in complex chemistry and polymer synthesis to the partnership, aiming to deliver top-tier solutions. With ongoing projects spanning Europe, the USA, and Asia, Seqens is dedicated to advancing PEKK manufacturing capabilities and ensuring high-quality outcomes in various applications. Bergerone's statement underscores Seqens' commitment to innovation and global leadership in providing advanced materials for critical industries, including healthcare and high-performance sectors.

Erwoan Pezron, Member of Arkema's Executive Committee and President of the High-Performance Polymers Business Line, expresses satisfaction in renewing and enhancing Arkema's technological partnership with Seqens, which began successfully 15 years ago. This renewal underscores Arkema's commitment to leveraging their long-standing collaboration with Seqens, focusing on advancing technological innovation and enhancing their mutual capabilities in the polymer sector. Pezron's statement highlights Arkema's confidence in the synergy between both companies, emphasizing their shared dedication to pushing the boundaries of high-performance polymer solutions for diverse industrial applications.

Arkema leverages its expertise in materials science to offer a premier portfolio of technologies catering to the increasing demand for sustainable materials. Positioned as a specialist in Specialty Materials, the company operates through three resilient and highly innovative segments: Adhesive Solutions, Advanced Materials, and Coating Solutions, which collectively accounted for approximately 92% of Group sales in 2023. Additionally, Arkema maintains a competitive Intermediates segment. The company delivers state-of-the-art technological solutions aimed at addressing challenges in emerging areas such as renewable energies, water access, recycling, urbanization, and mobility. Arkema prioritizes continuous engagement with stakeholders to drive innovation and sustainability. With operations spanning 55 countries and a workforce of 21,100 employees, Arkema achieved sales of around €9.5 billion in 2023, underscoring its global leadership in the specialty materials sector.